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1. Disease characteristics 32 
1.1 Name of the Disease (Synonyms): 33 
Hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome  34 
 35 
1.2 OMIM# of the Disease:  36 
238970 37 
 38 
1.3 Name of the Analysed Genes or DNA/Chromosome Segments: 39 
SLC25A15 or ORNT1 at 13q14.11 40 
 41 
1.4 OMIM# of the Gene(s): 42 
603861 43 
 44 
1.5 Mutational Spectrum: 45 
From 1999 to date, 39 mutations have been identified and associated to HHH syndrome.
1-5
 All 46 
mutations are located in the coding region and consist of: 24 missense mutations, 5 small insertions, 3 47 
small deletions, 4 nonsense mutations, 1 gross deletion, 1 micro-rearrangement, 1 intronic 48 
rearrangement. 49 
 50 
1.6 Analytical Methods: 51 
Sanger sequencing of coding regions and flanking intronic sequences of the SLC25A15 gene is the 52 
mainstay analytical method (NCBI reference sequence: NG_012248.1).  53 
 54 
1.7 Analytical Validation 55 
There are several steps in the analytical validation process. 56 
 57 
• Sequencing of both DNA strands (forward and reverse) is performed. Although most of 58 
variants have been identified by using this approach, intronic variants, large deletions, and 59 
duplications may require a different methodology. 60 
• It is recommended to check the identified heterozygous or homozygous variants also in 61 
patients’ parents. Proof of segregation further supports the diagnosis. 62 
• Pathogenicity of variants can be investigated by using an in vitro yeast cell model
6 
and by 63 





1.8 Estimated Frequency of the Disease 67 
(Incidence at birth ("birth prevalence") or population prevalence. If known to be variable between 68 
ethnic groups, please report): 69 
Up to date, more than 114 affected patients have been reported.
2-4
 In a recent review of 456 Urea 70 
Cycle Disorders (UCDs) patients prospectively followed between 2011 and 2015 by the E-IMD patient 71 
registry, 11 HHH syndrome patients were reported; thus, this disorder accounted for 2.4 % of all UCDs 72 
subjects.
8
 Although the HHH syndrome can be considered a very rare disease with a panethnic 73 
distribution, it has been more frequently reported in three countries: 26 patients (22%) were Canadian, 74 
as a result of a founder mutation in Quebec
1
, 18 patients (15%) were Italian and 14 patients (12%) 75 
were Japanese. In these three countries the HHH syndrome should not be considered a very rare 76 
disease since they account for about the 50% of all reported patients. 77 
 78 
1.9 Diagnostic Setting: 79 
 Yes. No. 80 
A. (Differential) diagnostics   81 
B. Predictive Testing   82 
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C. Risk assessment in Relatives   83 
D. Prenatal   84 
 85 
Comment: HHH syndrome is a rare recessive UCD
9
 caused by mutations in the SLC25A15 gene 
1-2,5
, 86 
which encodes for the mitochondrial ornithine carrier ORC1.
1,6  
Disease onset usually ranges from 87 
early infancy to childhood and, in rarer cases, adulthood. Patients typically present a variable clinical 88 
spectrum, ranging from a mild form with aversion for protein rich foods, developmental 89 
delay/intellectual disability, myoclonic seizures, ataxia and pyramidal dysfunction, to a more severe 90 
acute form with intermittent episodes of vomiting, confusion or coma, acute liver failure or hepatitis-like 91 
attacks.
3
 The chronic course of HHH syndrome is characterized by progressive encephalopathy with 92 
mental regression, and early signs of motor neuron dysfunction (spastic paraparesis).
2,3
 Multiple 93 
supratentorial stroke-like lesions have also been reported
, 
while ophthalmological signs are rare, with 94 
few patients showing severe retinal degeneration.
3,10
 The late onset cases present with 95 
hyperammonemia accompanied by lethargy and/ or coma and signs of severe liver dysfunction and /or 96 
life-threatening episodes of acute liver failure.
3
 97 
Asides from the severe neonatal form, there is no evidence of a direct correlation between age of 98 
onset, which is variable, and disease severity. No clear phenotype–genotype correlations could be 99 
found. Early diagnosis in infancy or childhood may improve the clinical outcome. The diagnosis relies 100 
on clinical signs and the peculiar metabolic triad of hyperammonemia, hyperornithinemia, and urinary 101 
excretion of homocitrulline. Besides this biochemical signature, patients may also present with 102 
increased plasma glutamine levels and intermittent elevation of urinary orotic acid.
3
 Some subjects 103 
also demonstrate low plasma creatine, as increased ornithine levels in this disorder inhibit 104 
arginine:glycine amidinotransferase, the first step of creatine synthesis.
10
 Furthermore, secondary 105 
creatine deficiency may be due to low cellular arginine availability.
11
 HHH syndrome enters in the 106 
differential diagnosis with other UCDs.
9
 107 
Parents and relatives of HHH syndrome affected probands should be checked for the presence of the 108 
identified mutation(s). If a family has an affected child and wishes to have more children, prenatal 109 
diagnosis should be discussed in detail during genetic counselling.  110 
 111 
2. Test characteristics 112 
 113 
 114 
2.1 Analytical Sensitivity 115 
(proportion of positive tests if the genotype is present) 116 
100%, if the genotype is also associated to at least one out of the three metabolic hallmarks, 117 
hyperammonemia, hyperornithinemia and homocitrullinuria. 118 
 119 
2.2 Analytical Specificity 120 
(proportion of negative tests if the genotype is not present) 121 




2.3 Clinical Sensitivity 126 
(proportion of positive tests if the disease is present) 127 
The clinical sensitivity can be dependent on variable factors such as age or family history. In such 128 
cases a general statement should be given, even if a quantification can only be made case by case. 129 
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When the diagnosis has been properly established based on clinical and genetic investigations, family 130 
history and biochemical results, very few negative tests are expected. When genetic testing is 131 
negative in a patient presenting only one or two out of the three metabolic hallmarks, 132 
hyperammonemia, hyperornithinemia and homocitrullinuria, a differential diagnoses should be 133 
considered. Notably, some patients may show an incomplete biochemical phenotype and HHH 134 
syndrome presents with a lower degree of hyperammonemia compared to other UCDs.
3,9 
These cases 135 
can likely result in a lower sensitivity. 136 
2.4 Clinical Specificity 137 
(proportion of negative tests if the disease is not present) 138 
The clinical specificity can be dependent on variable factors such as age or family history. In such 139 
cases a general statement should be given, even if a quantification can only be made case by case. 140 
Close to 100%. A precise quantification is difficult, since molecular testing of SLC25A15 gene is not 141 
performed on a routine basis in asymptomatic individuals. 142 
2.5 Positive clinical predictive value 143 
(life time risk to develop the disease if the test is positive) 144 
The positive clinical predictive value is 100%. Although the onset of symptoms is in most cases in 145 
infancy and childhood, the diagnosis is often delayed, with at least one fourth of cases identified in 146 
adulthood.
3 
Furthermore, a few patients presented the first disease manifestation as adults. As already 147 
described, genetic analysis does not have a prognostic value, since even in the same family and with 148 





2.6 Negative clinical predictive value 152 
(Probability not to develop the disease if the test is negative). 153 
Assume an increased risk based on family history for a non-affected person. Allelic and locus 154 
heterogeneity may need to be considered.  155 
Index case in that family had been tested: 156 
The negative clinical predictive value is nearly 100%. 157 
 158 
Index case in that family had not been tested: 159 
Genetic testing for a clinically unaffected individual is not indicated in this situation. It would only be 160 
undertaken if a variant in the SLC25A15 gene has been identified in the proband. 161 
3. Clinical Utility 162 
 163 
3.1 (Differential) diagnostics: The tested person is clinically affected 164 
(To be answered if in 1.9 "A" was marked) 165 
 166 
3.1.1 Can a diagnosis be made other than through a genetic test? 167 
 168 
No.  (continue with 3.1.4) 169 
Yes,  170 
 clinically.   171 
 imaging .   172 
 endoscopy.   173 
 biochemistry.   174 
 electrophysiology.  175 




3.1.2 Describe the burden of alternative diagnostic methods to the patient 180 
The blood and urine samplings for the serum ammonia and ornithine and urine homocitrulline (and 181 
orotic acid) measurements is a minor burden to the patient. The blood sampling is also used for the 182 
genetic analysis which helps to confirm the clinical diagnosis.  183 
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3.1.3 How is the cost effectiveness of alternative diagnostic methods to be judged?  184 
In some countries, like United States and Canada, HHH syndrome is included in the disease panel of 185 
expanded newborn screening programs, in others, like Italy, the cost of these tests is largely carried 186 
by the National Ministry of Public Health. Cost of biochemical and of genetic testing vary in different 187 
countries; however, since the SLC25A15 gene is small and thus accessible to Sanger sequencing, 188 
costs of genetic testing are low in comparison to a too late diagnosis during a metabolic crisis 189 
requiring intensive care treatment.  190 
 191 
3.1.4 Will disease management be influenced by the result of a genetic test? 192 
No.  193 
 194 
Yes.  195 
 Therapy (please describe)  An appropriate management with protein restricted diet, 196 
citrulline, arginine and essential aminoacid supplements 197 
combined with ammonia scavengers allows almost normal life 198 
duration. Chronic therapy prevents hyperammonemia and 199 
liver disease but does not affect the spastic paraparesis. 
3 200 
Acute treatment is similar to other UCDs.
9
 Protein intake must 201 
be stopped for 24 hours, and intravenous fluids in 202 
combination with first-line medications must be initiated. 203 
Arginine (and/ or citrulline) must be administered to replace 204 
the missing urea cycle intermediates and to allow protein 205 
synthesis. Ammonia scavengers, sodium benzoate and 206 
sodium phenylbutyrate, are used for bypassing the urea 207 
cycle. Benzoate captures glycine to generate hippurate; 208 
phenylacetate is conjugated with glutamine generating 209 
phenylacetylglutamine. Long-term treatment consists of a low 210 
protein diet supplemented with citrulline, arginine, or 211 
ornithine. Protein restriction may be combined with sodium 212 
benzoate.
3,9
 If plasma creatine levels are low, creatine 213 
supplementation should be instituted.
10,11
 Citrulline 214 
supplementation has been shown to allow better metabolic 215 




 Prognosis (please describe)  Prognosis is highly variable ranging from mild neurological 218 
involvement to a severely disabling disease. 7 patients out of 219 
the published 114 patients, with a known vital status, died. 220 




 Management (please describe) Since HHH syndrome can affect different systems, follow-up 223 
by a multidisciplinary team is crucial. In particular, as the 224 
evolution of spastic paraparesis is unaffected by 225 
pharmacological treatment, regular physical and occupational 226 
therapy as well as drugs able to reduce spasticity are 227 
recommended; periodical clinical and neurophysiological 228 
evaluation of the progression of the disease is advisable as in 229 
other inherited spastic parapaplegias.12 The metabolic follow-230 
up includes measurement of plasma ammonia and amino 231 
acids (and possibly creatine) and urinary homocitrulline and 232 





3.2 Predictive Setting: The tested person is clinically unaffected but carries an 236 
increased risk based on family history 237 
  (To be answered if in 1.9 "B" was marked) 238 
3.2.1 Will the result of a genetic test influence lifestyle and prevention? 239 
 240 
If the test result is positive (please describe) Although an appropriate and chronic therapy (see 3.1.4) 241 
prevents hyperammonemia and liver disease, it does not prevent the spastic paraparesis progression. 242 
If positive, the test will greatly influence the choice of career and life planning.  243 
 244 
 245 
If the test result is negative (please describe) If the mutation is identified in the index case and not in 246 
the unaffected proband, regular examinations are not necessary. Follow-up is recommended only if 247 
the disease-causing mutation could not be identified.  248 
3.2.2 Which options in view of lifestyle and prevention does a person at-risk have if no genetic 249 
test has been done (please describe)? 250 
That person at-risk should avoid a protein-enriched diet in order to prevent life-threatening 251 
hyperammonemic crisis. 252 
 253 
3.3 Genetic risk assessment in family members of a diseased person 254 
  (To be answered if in 1.9 "C" was marked) 255 
3.3.1 Does the result of a genetic test resolve the genetic situation in that family? 256 
Yes, a molecular diagnosis in an affected individual can resolve the genetic situation in that family. A 257 
positive test in a patient may lead, at adult age, to test the carriership of his/her partner.  258 
 259 
3.3.2 Can a genetic test in the index patient save genetic or other tests in family members? 260 
No, if a disease-causing mutation is identified in the index patient, family members should be tested in 261 
order to avoid a possible mutation’s spreading in the adult age.  262 
 263 
3.3.3 Does a positive genetic test result in the index patient enable a predictive test in a family 264 
member? 265 
If a disease-causing mutation is identified in the index patient, it may help to quickly identify another 266 
affected relative since very often affected patients show an aversion to protein-rich foods.  267 
 268 
 269 
3.4 Prenatal diagnosis 270 
  (To be answered if in 1.9 "D" was marked) 271 
3.4.1 Does a positive genetic test result in the index patient enable a prenatal diagnosis? 272 
Yes. Prenatal diagnosis should be performed by molecular analysis. 273 
 274 
 275 
4. If applicable, further consequences of testing 276 
Please assume that the result of a genetic test has no immediate medical consequences. Is there any 277 
evidence that a genetic test is nevertheless useful for the patient or his/her relatives? (Please 278 
describe) 279 
Genetic testing for SLC25A15 variants will provide a molecular diagnosis, allowing an appropriate 280 
management of the patient, reducing the risk of hyperammonemia and metabolic decompensation. It 281 
will also define the inheritance patterns and enable effective genetic counselling.  282 
 283 
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